Here are the Top Health stories of the day
India's Omicron count crosses 1,700-mark
NMC nod to DM cardiology course at PGIMS Rohtak
In a major milestone for the Pt Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, the Medical Assessment and Rating Board (MARB) of the National Medical Commission (NMC) has given its nod to the institute for introducing the Doctorate of Medicine (cardiology) course.
For now, PGIMS Rohtak would run the course with an intake capacity for two seats, reports The Tribune.
For more information, check out the full story on the link below:
NMC nod to DM Cardiology Course at PGIMS Rohtak
NBE begins registration for Formative Assessment Test 2021
The National Board of Examinations (NBE) has activated the portal for Registration of NBEMS Trainees for Formative Assessment Test FAT 2021 for DNB/DrNB/FNB Trainees.
The FAT Theory Examination, 2021 is going to be conducted on 19th February 2022.
The Registration of NBEMS trainees for Formative Assessment Test 2021 (FAT-2021) can be done through NBEMS Online Portal only till 18th January, 2022 (till 11:55 PM).
For more details, check out the full story on the link below:
Telangana begins termination proceedings against 38 assistant Professors
Taking strict action against doctors for long term "unauthorised absence" in various institutes, Director of Medical Education, Telangana has begun termination proceedings against 38 assistant Professors.
The enquiry committee constituted to look into the matter has already recommended their termination and with this the department has now issued show-cause notices to the 38 doctors asking them to submit their explanations as to why they shouldn't be terminated from service.
For more details, check out the full story on the link below:
Telangana begins termination proceedings against 38 assistant Professors
13 pharma majors to launch anti-COVID drug Molnupiravir
Thirteen Indian pharmaceutical companies, including Torrent, Cipla, Sun Pharma, Dr Reddy's, Natco, Mylan, Hetero, Optimus will be manufacturing Molnupiravir, which is being developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck.
With the Drugs Controller General of India (DCGI) emergency use authorisation for the generic version of Merck and Ridgeback's oral COVID-19 antiviral medicine Molnupiravir, pharma majors including Cipla, Sun Pharma, Torrent, Natco, Optimus, Hetero, Dr Reddys, and others, are gearing up to launch the oral anti-covid drug Molnupiravr with the aim of strengthening the COVID-19 battle in the country.
For more details, check out the full story on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.